Tokyo Electron Limited (TYO:8035)

Oncternal Therapeutics Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	2,426,083	2,431,568	1,830,527	2,209,025	2,003,805	1,399,102
Revenue Growth (YoY)	21.68%	32.83%	-17.13%	10.24%	43.22%	24.11%
Cost of Revenue	1,289,847	1,285,280	1,000,257	1,224,617	1,091,983	834,157
Gross Profit	1,136,236	1,146,288	830,270	984,408	911,822	564,945
Selling, General & Admin	201,232	198,950	171,133	175,488	154,295	107,611
Research & Development	258,722	250,017	202,873	191,196	158,256	136,648
Operating Expenses	459,954	448,967	374,006	366,684	312,551	244,259
Operating Income	676,282	697,321	456,264	617,724	599,271	320,686
Interest & Investment Income	3,664	3,579	2,567	2,435	1,575	778
Earnings From Equity Investments	3,001	3,001	3,388	2,968	1,721	1,110
Currency Exchange Gain (Loss)	-961	-929	-4,148	-1,401	-2,447	-3,147
Other Non Operating Income (Expenses)	5,690	4,755	5,113	3,459	1,604	2,676
EBT Excluding Unusual Items	687,676	707,727	463,184	625,185	601,724	322,103
Gain (Loss) on Sale of Assets	-1,256	-1,166	10,033	109	71	-1,330
Asset Writedown	-447	-447	-	-438	-	-
Other Unusual Items	4,859	-1	221	-	-5,097	-3,736
Pretax Income	690,832	706,113	473,438	624,856	596,698	317,037
Income Tax Expense	155,087	161,980	109,475	153,272	159,622	74,096
Earnings From Continuing Operations	535,745	544,133	363,963	471,584	437,076	242,941
Net Income	535,745	544,133	363,963	471,584	437,076	242,941
Net Income to Common	535,745	544,133	363,963	471,584	437,076	242,941
Net Income Growth	25.81%	49.50%	-22.82%	7.90%	79.91%	31.17%
Shares Outstanding (Basic)	459	460	464	468	467	467
Shares Outstanding (Diluted)	460	461	466	470	469	469
Shares Change (YoY)	-0.83%	-0.95%	-0.82%	0.10%	0.02%	-1.70%
EPS (Basic)	1166.53	1182.40	783.75	1007.82	935.95	520.74
EPS (Diluted)	1163.42	1179.08	781.20	1003.86	931.30	517.76
EPS Growth	26.86%	50.93%	-22.18%	7.79%	79.87%	33.44%
Free Cash Flow	289,294	423,800	317,727	359,373	227,234	92,082
Free Cash Flow Per Share	628.23	918.33	681.96	765.00	484.18	196.25
Dividend Per Share	592.000	592.000	393.000	503.667	467.667	260.333
Dividend Growth	50.64%	50.64%	-21.97%	7.70%	79.64%	32.82%
Gross Margin	46.83%	47.14%	45.36%	44.56%	45.51%	40.38%
Operating Margin	27.88%	28.68%	24.93%	27.96%	29.91%	22.92%
Profit Margin	22.08%	22.38%	19.88%	21.35%	21.81%	17.36%
Free Cash Flow Margin	11.92%	17.43%	17.36%	16.27%	11.34%	6.58%
EBITDA	742,584	759,586	508,676	660,819	636,204	354,728
EBITDA Margin	30.61%	31.24%	27.79%	29.92%	31.75%	25.35%
D&A For EBITDA	66,302	62,265	52,412	43,095	36,933	34,042
EBIT	676,282	697,321	456,264	617,724	599,271	320,686
EBIT Margin	27.88%	28.68%	24.93%	27.96%	29.91%	22.92%
Effective Tax Rate	22.45%	22.94%	23.12%	24.53%	26.75%	23.37%

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.